Plain-English translation of NCT06275685 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing SeizureWise, an algorithm that uses data from a wearable wristband called EmbracePlus to forecast when generalized tonic-clonic seizures (the most common type) might occur. The wristband tracks your body's signals — like heart rate and movement patterns — and the algorithm looks for patterns that may predict seizures. Researchers want to see if this prediction tool is accurate and whether knowing a seizure might be coming helps people feel more in control and improves their quality of life.
Many people with epilepsy live with the fear and uncertainty of not knowing when a seizure will strike, which can affect sleep, work, relationships, and mental health. This trial exists to see whether predicting seizures could give people more warning and control, potentially reducing anxiety and helping them plan their lives better.
You likely qualify if…
You likely don't qualify if…
You will wear the EmbracePlus wristband, which continuously collects data about your heart rate, movement, and other body signals. The study has multiple phases: first, the device will gather data to help develop the prediction algorithm (with results kept hidden from you), and then you will be randomly assigned to one of two groups—either one that sees your health data visualizations without predictions, or one that also receives seizure risk forecasts. Throughout the study, you'll likely fill out surveys and keep a daily diary to help researchers understand how the tool affects your seizure management and quality of life.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States